Tag Archives: NASDAQ:SQNM
Sequenom, Inc. (NASDAQ:SQNM) Revenue Surges, Assured Guaranty Ltd. (NYSE:AGO) on Earnings Front- NYSE:AGO
Sequenom, Inc. (NASDAQ:SQNM), a life sciences firm giving innovative genetic analysis solutions, on Thursday declared revenue of $38.5 million for the first quarter of this year, a hike of 158% in contrast to revenue of $14.9 million for the …
Illumina (NASDAQ:ILMN) Declares Sharp Boost in Fiscal Fourth Quarter Profit on Business Unit Sale
Illumina, Inc (NASDAQ:ILMN) announced a sharp boost in fiscal Q4 profit on Monday after the sale of a business unit to Amgen, Inc (NASDAQ:AMGN).
Genetic analysis Instrument Company booked a $48.6 million gain from the pre-tax sale of its stake …
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) Updates Claim of a Healthy Pipeline
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) lately gave an update on its pipeline. Isis Pharmaclaims of a healthy pipeline. The firm thinks 5 of its pipeline candidates can get acceptance within the coming five years. Isis Pharmaanticipates data (phase II or phase …
Herbalife (NYSE:HLF) Symbolized as Compelling Buy below $70 – HLF, GMCR, LULU, DNDN, SQNM, MRK, PFE, HLF, CELG
On Friday DA Davison expert Timothy Ramey reported that Herbalife (NYSE:HLF)is a “compelling buy” at any price less than $70 per share, in spite of disapproval of the firm by hedge fund manager Bill Ackman of Pershing Square Capital Management. …
Illumina Inc. (NASDAQ:ILMN) Down to Knees after Roche Offer Refused – ILMN, LIFE, LMNX, VIVUS, VVUS, PFE, DNDN, HLF, SQNM
Illumina Inc. (NASDAQ:ILMN)plunged almost 8.5% in premarket session on Monday following Roche Holding AG Chairman Franz Humer reported in an interview that the firm does not intend to purchase the gene sequencing expert.
Illumina(ILMN) is certainly off the table, Humerreported …
Emergent Biosolutions (NYSE:EBS) Issues FY 2012 Results; Revenue Misses Estimates – WPI, MYL, PPHM, VVUS, BSX, ILMN, SQNM, UNH
Emergent BiosolutionsInc (NYSE:EBS) on Monday reported its preliminary fiscal year 2012 financial results, projecting revenues slightly lower than Wall Street analysts’ forecasts. Biopharmaceutical Company also offered 2013 revenue outlook lower than forecasts.
The company projects net income in the range …















